Literature DB >> 8963166

Bilateral transient visual obscurations with headaches during alpha-II interferon therapy: a case report.

M Detry-Morel1, A Boschi, M Gehenot, A Geubel.   

Abstract

A 40 year-old woman receiving alpha interferon therapy for chronic active hepatitis C presented transient bilateral visual obscurations with associated visual field defects and headaches, with elevated cryoglobulin levels. These manifestations mimicked the clinical picture of migraine and were associated with worsening of previous moderate Raynaud's syndrome and diffuse paraventricular lesions of the white matter seen in cerebral MRI. Bilateral posterior cerebral transient ischemic episodes rather than an anterior visual pathway lesion were thought to be responsible for the clinical symptoms though the exact role of interferon in these vasospastic-like disorders remains speculative. Their possible relationship with increased cryoglobulinemia is uncertain. We suggest that Raynaud's phenomenon may have a predisposing role for these manifestations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8963166     DOI: 10.1177/112067219500500413

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  3 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  Headache and liver disease: is their relationship more apparent than real?

Authors:  Roberto R Rodríguez; Jorge Saccone; María A Véliz
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 3.  The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis.

Authors:  Jun-Ying Liu; Yun-Jian Sheng; Huai-Dong Hu; Qing Zhong; Jing Wang; Shi-Wen Tong; Zhi Zhou; Da-Zhi Zhang; Peng Hu; Hong Ren
Journal:  Virol J       Date:  2012-09-06       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.